Instem CSO, Dr Gordon Baxter, was recently interviewed by Drug Target Review for an in-depth editorial on Target Safety Assessment.
Download the article
Watch the demo
Includes Powerful New In Silico Models and First-to-Market Software Capabilities
Read the news
Join the journey with us by visiting one of our bi-weekly industry Blogs
Newly Added Services to Support Latest Regulatory Guidance and Growing Demand for Alternative Testing Methods
Acquisition of PDS Life Sciences Consolidates Non-Clinical Market; Further Extends Instem’s Leadership in Study Management and Regulatory SEND Submission Support
Powerful New In Silico Models and First-to-Market Software Capabilities to Deliver Further Efficiencies and Increased Regulatory Compliance
To help you better evaluate our software or services, we believe an initial, no pressure Web session is the way to go.
We are excited that you have decided to take the next step with Instem. To provide you with an accurate quotation, we ask that you fill out our form.
© 2022 Instem Group of Companies